Application and future prospects of bispecific antibodies in the treatment of colorectal cancer

Over the past decade, the incidence of colorectal cancer (CRC) has continued to rise, imposing a substantial disease burden on both patients and society. Improvements in treatment strategies—including surgery, chemotherapy, targeted therapy, and immunotherapy—have significantly improved clinical outcomes. Immunotherapy, particularly immune checkpoint inhibitors, has shown promising efficacy in rectal cancer studies. Nevertheless, multiple CRC subtypes are still hindered by an immunosuppressive tumor microenvironment, the development of therapeutic resistance, and low response rates to immunotherapy, collectively limiting further gains in clinical benefit. As an emerging therapeutic modality, bispecific antibodies (BsAbs) possess two binding specificities, enabling them to bind simultaneously to the same or different antigens, thereby generating multifaceted anti-tumor effects. Therefore, BsAbs can help overcome treatment resistance and potentiate antitumor immune responses. To date, numerous BsAbs have been used in clinical trials to assess their safety and efficacy across diverse CRC subtypes. This review summarizes the main classes of BsAbs used for CRC treatment, focusing on their mechanisms of action and recent advances in clinical research. We further discuss existing challenges for BsAbs and the potential strategies.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-12
DOI
https://doi.org/10.3389/fimmu.2026.1995473
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Application and future prospects of bispecific antibodies in the treatment of colorectal cancer

Kai Long, Qipeng Yao, Yihua Zeng, Chao Chen
Frontiers in Immunology
Monoclonal and Polyclonal Antibodies Research
article

Application and future prospects of bispecific antibodies in the treatment of colorectal cancer

Kai Long, Qipeng Yao, Yihua Zeng, Chao Chen
article en

Abstract

Over the past decade, the incidence of colorectal cancer (CRC) has continued to rise, imposing a substantial disease burden on both patients and society. Improvements in treatment strategies—including surgery, chemotherapy, targeted therapy, and immunotherapy—have significantly improved clinical outcomes. Immunotherapy, particularly immune checkpoint inhibitors, has shown promising efficacy in rectal cancer studies. Nevertheless, multiple CRC subtypes are still hindered by an immunosuppressive tumor microenvironment, the development of therapeutic resistance, and low response rates to immunotherapy, collectively limiting further gains in clinical benefit. As an emerging therapeutic modality, bispecific antibodies (BsAbs) possess two binding specificities, enabling them to bind simultaneously to the same or different antigens, thereby generating multifaceted anti-tumor effects. Therefore, BsAbs can help overcome treatment resistance and potentiate antitumor immune responses. To date, numerous BsAbs have been used in clinical trials to assess their safety and efficacy across diverse CRC subtypes. This review summarizes the main classes of BsAbs used for CRC treatment, focusing on their mechanisms of action and recent advances in clinical research. We further discuss existing challenges for BsAbs and the potential strategies.

Frontiers in ImmunologyVol. 17
University of Electronic Science and Technology of China (CN), Sichuan University (CN), West China Medical Center of Sichuan University (CN), West China Hospital of Sichuan University (CN), Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (CN)
Good health and well-being
Monoclonal and Polyclonal Antibodies Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon